TY - JOUR
T1 - Peritoneal Metastases from Prostate Carcinoma Treated with 177Lu-PSMA-I&T
AU - van Golen, Larissa W.
AU - Seijkens, Tom T. P.
AU - de Feijter, Jeantine M.
AU - Vogel, Wouter
N1 - Funding Information: Conflicts of interest and sources of funding: W. V. has unrestricted research grant from Novartis related to Lutetium-177-PSMA therapy. The other authors have no conflicts to report. Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - A 71-year-old man was referred for 177Lu-PSMA therapy. He had metastatic castration-resistant prostate cancer, progressive on several treatment lines, with current PSA 260 ?g/L and deteriorating condition. CT showed ascites with omental and peritoneal metastases, all positive on PSMA PET/CT. He was treated with 4 cycles of 7.4 GBq (0.2 Ci) 177Lu-PSMA-I&T. Posttherapy scans showed good targeting of all metastases. After 4 cycles, PSA had dropped to 44 ?/L. Four months after the fourth cycle, the patients' general condition had significantly improved, and PSA had decreased to 7.0 ?g/L.
AB - A 71-year-old man was referred for 177Lu-PSMA therapy. He had metastatic castration-resistant prostate cancer, progressive on several treatment lines, with current PSA 260 ?g/L and deteriorating condition. CT showed ascites with omental and peritoneal metastases, all positive on PSMA PET/CT. He was treated with 4 cycles of 7.4 GBq (0.2 Ci) 177Lu-PSMA-I&T. Posttherapy scans showed good targeting of all metastases. After 4 cycles, PSA had dropped to 44 ?/L. Four months after the fourth cycle, the patients' general condition had significantly improved, and PSA had decreased to 7.0 ?g/L.
KW - Lu-PSMA
KW - PSMA PET/CT
KW - peritoneal omental metastases
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85151819341&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/RLU.0000000000004577
DO - https://doi.org/10.1097/RLU.0000000000004577
M3 - Article
C2 - 36716524
SN - 0363-9762
VL - 48
SP - 422
EP - 425
JO - Clinical nuclear medicine
JF - Clinical nuclear medicine
IS - 5
ER -